The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells

Oncol Rep. 2017 Jul;38(1):488-496. doi: 10.3892/or.2017.5675. Epub 2017 May 30.

Abstract

Multiple myeloma (MM) is an incurable hematologic malignancy because of its drug resistance. Pterostilbene (Pter) is found mainly in blueberries and grapes. The effects of Pter and its exact pharmacologic mechanisms on chemoresistant myeloma are not known. Herein, we investigated the anti-myeloma activity of Pter in bortezomib-resistant cell line H929R and explored the related mechanism of action for the first time. We found that Pter inhibited proliferation of H929R cells and promoted apoptosis of the cells through a caspase-dependent pathway, loss of mitochondrial membrane potential, and activation of Akt and p38 mitogen-activated protein kinase (MAPK) signaling pathways. DNA damage and S-phase arrest might be involved in Pter-related toxicity in H929R cells. Pter and the histone deacetylase inhibitors panobinostat or vorinostat inhibited proliferation of H929R cells in a synergistic manner. These data supported that Pter might be a promising natural compound for relapsed/refractory myeloma therapy, especially against myeloma resistant to bortezomib chemotherapy.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects
  • Blueberry Plants / chemistry
  • Bortezomib / pharmacology
  • Bortezomib / therapeutic use
  • Caspases / metabolism
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • DNA Damage / drug effects
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Histone Deacetylase Inhibitors / pharmacology*
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Hydroxamic Acids / pharmacology
  • Hydroxamic Acids / therapeutic use
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • MAP Kinase Signaling System / drug effects*
  • Membrane Potential, Mitochondrial / drug effects
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Panobinostat
  • S Phase Cell Cycle Checkpoints / drug effects
  • Stilbenes / pharmacology*
  • Stilbenes / therapeutic use
  • Vorinostat
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Stilbenes
  • pterostilbene
  • Vorinostat
  • Bortezomib
  • Panobinostat
  • p38 Mitogen-Activated Protein Kinases
  • Caspases